{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-003216","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.359880+00:00","generated_at":"2026-06-26T00:53:09.755053+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aligos Q1 net loss $35.6M (-$0.84/sh); HBV STOPS/ASO programs terminated; cash $183.2M","bullets":["Net loss of $35.6M ($0.84 per share) vs $27.7M ($0.74) in Q1 2021; R&D expense rose to $31.7M.","Cash, equivalents and marketable securities $183.2M at March 31, 2022; runway into first half 2024.","Terminated STOPS and ASO HBV programs in Q1 due to insufficient antiviral activity and poor tolerability.","ALG-000184 (HBV CAM) 28-day top-line data expected Q2 2022; 12-week cohort initiating Q3.","COVID PI candidate ALG-097558 7-20x more potent than nirmatrelvir vs variants; Phase 1 CTA planned H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-003216","json":"https://secwatch.observer/filing/0001171843-22-003216.json","markdown":"https://secwatch.observer/filing/0001171843-22-003216.md","text":"https://secwatch.observer/filing/0001171843-22-003216.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184322003216/0001171843-22-003216-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184322003216/f8k_050422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:53:09.755053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}